Konjenital Miyopatiler
Özet
Konjenital miyopatiler, genellikle erken çocukluk döneminde başlayan hipotoni, kas güçsüzlüğü ve motor gelişim geriliği ile karakterize nadir ve heterojen bir kalıtsal nöromüsküler hastalık grubudur. Hastalık, iskelet kası sarkomer yapısındaki protein defektlerine bağlı olarak gelişir ve kesin tanı klinik bulgular, kas biyopsisi, görüntüleme ve ileri genetik analizlerin bütüncül değerlendirilmesini gerektirir. Tedavide güncel olarak küratif bir yöntem bulunmamakla birlikte, destekleyici bakımın yanı sıra gen tedavisi ve yeni terapötik modaliteler üzerine çalışmalar yoğun bir şekilde devam etmektedir.
Congenital myopathies are a heterogeneous group of rare hereditary neuromuscular disorders characterized by early-onset hypotonia, muscle weakness, and delayed motor development. Diagnosis primarily involves a combination of clinical evaluation, muscle biopsy, imaging, and advanced genetic analysis due to the complex architectural defects in sarcomeric proteins. While there is no current curative treatment, management focuses on supportive care, with significant ongoing research into emerging gene therapies and new therapeutic modalities.
Referanslar
Darras BT, Jones HR, Ryan MM, De Vivo DC. Neuromuscular Disorders of Infancy, Childhood and Adolescence: a clinician’s approach. Second edition: Elsevier;2014. p. 499-537.
Claeys KG. Congenital myopathies: an update. Developmental Medicine & Child Neurology, 2020, 62.3: 297-302.
Tubridy N, Fontaine B, Eymard B. Congenital myopathies and congenital muscular dystrophies. Curr Opin Neurol. 2001; 14: 575–82.
Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;132(pt 11):3175-3186.
Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord 2000;10(1):1-9.
Maggi L, Scoto M, Cirak S et al. Congenital myopathies-clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord 2013;23:195–205.
Karakaya, Mert. "Konjenital Myopatilerde Klinik, Histopatolojik ve Genetik Değerlendirme." (2014).
North KN, Wang CH, Clarke N et al. Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders, 2014, 24.2: 97-116.
Venance, Shannon L. "Approach to the patient with HyperCKemia." CONTINUUM: Lifelong Learning in Neurology 22.6 (2016): 1803-1814.
Munot P, Lashley D, Jungbluth H et al. Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia. Neuromuscular Disorders, 2010, 20.12: 796-800.
Cruz PMR, Sewry CA, Beeson D, et al.Congenital myopathies with secondary neuromuscular transmission defects; a case report and review of the literature. Neuromuscular Disorders,2014: 24(12), 1103-1110.
North KN. Clinical approach to the diagnosis of congenital myopathies. Semin Pediatr Neurol, 2011. 18(4): p. 216-20.
Klein A, Jungbluth H, Clement E et al. Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations. Arch Neurol 2011, 68(9):1171-1179
Carlier RY, Quijano-Roy S. Myoimaging in congenital myopathies. In Seminars in pediatric neurology 2019:29,30-43.
Kiiski K, Lehtokari VL, Manzur AY et al. A large deletion affecting TPM3, causing severe nemaline myopathy. J Neuromuscul Dis 2:433- 438.
Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain, 1956, 79.4: 610-621.
Wang CH, Dowling JJ, North K et al. Consensus statement on standard of care for congenital myopathies. Journal of child neurology, 2012, 27.3: 363-382.
Natera-de Benito D, Ortez C, Jou C et al. The phenotype and genotype of congenital myopathies based on a large pediatric cohort. Pediatric Neurology, 2021, 115: 50-65.
Gonorazky HD, Bönnemann CG, Dowling JJ. The genetics of congenital myopathies. Handbook of clinical neurology,2018(148): 549-564.
Colombo I, Scoto M, Manzur AY et al.Congenital myopathies: natural history of a large pediatric cohort. Neurology, 2015, 84.1: 28-35.
Jungbluth H, Sewry CA, Muntoni F. Core myopathies. In: Seminars in pediatric neurology. WB Saunders, 2011. p. 239-249
Mah JK, Joseph JT. An overview of congenital myopathies. Continuum: Lifelong Learning in Neurology, 2016, 22.6: 1932-1953.
Shuaib A, Martin JM, Mitchell LB et al. Multicore myopathy: not always a benign entity. Can J Neurol Sci 1988;15:10-4.
Clarke NF, Waddell LB, Cooper ST et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mutat 2010; 31: 1544–5.
Sewry CA,Wallgren-Pettersson C. Myopathology in congenital myopathies. Neuropathology and applied neurobiology, 2017, 43.1: 5-23.
Monnier N, Romero NB, Lerale J et al. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet 2001;10:2581-92
Todd JJ, Razaqyar MS, Witherspoon JW et al. Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings. Frontiers in Neurology. 2018;9:118.
Brislin RP, Theroux MC. Core myopathies and malignant hyperthermia susceptibility: a review. Paediatr Anaesth, 2013. 23(9): p. 834-41.
Sei Y, Sambuughin NN, Davis EJ et al. Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 101:824-830, 2004.
Topaloglu, H. Core myopathies–a short review. Acta Myologica 2020, 39(4), 266.
Harris, E, Marini-Bettolo C, Töpf A et al. MEGF10 related myopathies: A new case with adult onset disease with prominent respiratory failure and review of reported phenotypes. Neuromuscular Disorders 2018, 28(1), 48-53.
Lornage X, Romero NB, Grosgogeat CA et al. ACTN2 mutations cause "Multiple structured Core Disease" (MsCD). Acta Neuropathol. 2019;137(3):501-519.
Muelas N, Hackman P, Luque H et al. MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy. Neurology 2010;75:732-41.
Estan MC, Fernandez-Nunez E, Zaki MS et al. Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nature Commun. 2019(10): 797.
Yiş, U, Hiz S, Güneş S et al. Dihydropyridine receptor congenital myopathy in a consangineous Turkish family. Journal of neuromuscular diseases 2019:6(3), 377-384.
Villar-Quiles RN, Catervi F, Cabet E et al. ASC-1 is a cell cycle regulator associated with severe and mild forms of myopathy. Ann Neurol 2020;87:217-32.
Romero NB, Sandaradura SA, Clarke NF. Recent advances in nemaline myopathy. Curr Opin Neurol, 2013. 26(5): p. 519-26.
Finsterer J, Stöllberger C. Review of cardiac disease in nemaline myopathy. Pediatric neurology, 2015: 53(6), 473-477.
Wallgren-Pettersson C, Sewry CA, Nowak KJ et al. Nemaline myopathies. Semin Pediatr Neurol. 2011;18:230-238.
Sasaki M, Yoneyama H, Nonaka I. Respiratory muscle involvement in nemaline myopathy.Pediatric Neurology,1990: 6(6), 425-427.
North KN, Laing NG, Wallgreen-Pettersson C. Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy. Journal of medical genetics, 1997, 34.9: 705.
Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A et al. Sporadic late-onset nemaline myopathy: clinicopathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017,12.1:1-12.
Ryan MM, Ilkovski B, Strickland CD et al. Clinical course correlates poorly with muscle pathology in nemaline myopathy. Neurology, 2003, 60.4: 665-673.
Marttila M, Hanif M, Lemola E et al. Nebulin interactions with actin and tropomyosin are altered by diseasecausing mutations. Skelet Muscle. 2014;4:15.
Dubowitz V, Sewry CA, Oldfors A. (2020). Muscle biopsy e-book: a practical approach. Elsevier Health Sciences.
Lehtokari VL, Kiiski K, Sandaradura SA et al. Mutation update: the spectra of nebulin variants and associated myopathies. Hum Mut 2014:35(12), 1418-1426.
Sewry CA, Laitila JM, Wallgren-Pettersson C. Nemaline myopathies: a current view. Journal of Muscle Research and Cell Motility, 2019, 40.2: 111-126.
Kiiski KJ, Lehtokari VL, Vihola AK et al. Dominantly inherited distal nemaline/cap myopathy caused by a large deletion in the nebulin gene. Neuromuscul Disord 2019(29):97–107.
Agrawal PB, Strickland CD, Midgett C, et al. Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol. 2004;56:86-96.
Cassandrini D, Trovato R, Rubegni A et al. Congenital myopathies: clinical phenotypes and new diagnostic tools. Italian journal of pediatrics,2017: 43(1), 1-16.
Ravenscroft, G, Miyatake S, Lehtokari VL et al. Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. The American Journal of Human Genetics 2013, 93(1), 6-18.
Avasthi KK, Agrawal S, Panigrahi I. KLHL40 mutation associated with severe nemaline myopathy, fetal akinesia, and cleft palate. Journal of Pediatric Neurosciences 2019, 14(4), 222.
Fox MD, Carson VJ, Feng HZ, et al.TNNT1 nemaline myopathy: natural history and therapeutic frontier. Human Molecular Genetics 2018, 27(18), 3272-3282.
Sandaradura SA, Bournazos A, Mallawaarachchi A et al. Nemaline myopathy and distal arthrogryposis associated with an autosomal recessive TNNT3 splice variant. Human Mutation 2018, 39(3), 383-388.
Yuen M, Sandaradura SA, Dowling JJ et al. Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. J Clin Investig 2014(124):4693–4708.
Miyatake S, Mitsuhashi S, Hayashi YK et al. Biallelic mutations in MYPN, encoding myopalladin, are associated with childhood-onset, slowly progressive nemaline myopathy. The American Journal of Human Genetics 2017, 100(1), 169-178.
Spiro AJ, Shy GM, Gonatas NK: Myotubular myopathy. Archives of Neurology 1966, 14:1-14.
Romero NB. Centronuclear myopathies: A widening concept. Neuromuscul Disord 2010;20(4): 223-228.
Lawlor MW, Beggs AH, Buj-Bello A et al. Skeletal muscle pathology in X-linked myotubular myopathy: review with cross- species comparisons. J Neuropathol Exp Neurol 2016; 75: 102–10.
Bevilacqua JA, Bitoun M, Biancalana V et al., « Necklace » fibers, a new histologicial marker of late-onset MTM1-related centronuclear myopathy. Acta Neuropathol 2009; 117:283–291.
Majczenko K, Davidson AE, Piragua SC et al. Dominant mutation of CCDC78 in a unique congenital myopathy with prominent internal nuclei and atypical cores. The American Journal of Human Genetics, 2012, 91.2: 365-371.
Amburgey K, Tsuchiya E, De Chastonay S et al. A natural history study of X-linked myotubular myopathy. Neurology 2017,89(13):1355–1364.
Savarese M, Musumeci O, Giugliano T et al. Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. Neuromuscul Disord 2016(26): 292–299.
Werlauff U, Petri H, Witting N, Vissing J. Frequency and phenotype of myotubular myopathy amongst Danish patients with congenital myopathy older than 5 years. J Neuromuscul Dis 2015;2:167–174.
Tsai TC, Horinouchi H, Noguchi S et al. Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism. Neuromuscul Disord 2005,15(3):245–252.
Bitoun M, Bevilacqua JA, Eymard B et al. A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation. Neurology 2009, 72:93–95.
Bohm J, Yis U, Ortac R, et al. Case report of intrafamilial variability in autosomal recessive centronuclear myopathy associated to a novel BIN1 stop mutation. Orphanet J Rare Dis 2010;5:35.
Toussaint, A, Cowling BS, Hnia K et al. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies. Acta neuropathologica 2011, 121(2), 253-266.
Cabrera-Serrano M, Mavillard F, Biancalana V et al. A Roma founder BIN1 mutation causes a novel phenotype of centronuclear myopathy with rigid spine. Neurology 2018, 91(4), e339-e348.
Brooke MH. Congenital fiber type disproportion. Clinical studies in myology,1973; 147-159.
Papadimas GK, Xirou S, Kararizou E, Papadopoulos C. Update on Congenital Myopathies in Adulthood. International Journal of Molecular Sciences 2020, 21(10), 3694.
O'Grady GL, Best HA, Oates EC, et al: Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. Eur J Hum Genet 2015(23):883-886.
Moreno, CAM, de Paula Estephan E, Fappi A et al.Congenital fiber type disproportion caused by TPM3 mutation: A report of two atypical cases. Neuromuscular Disorders2020, 30(1), 54-58.
Weterman MAJ,Barth PG, van Spaendonck-Zwarts KY et al. Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy. Brain, 2013, 136.1: 282-293.
Fiorillo C, Astrea G, Savarese M et al. MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet J Rare Dis. 2016;11:91.
O’grady GL, Best HA, Sztal TE et al.Variants in the oxidoreductase PYROXD1 cause early-onset myopathy with internalized nuclei and myofibrillar disorganization. The American Journal of Human Genetics 2016, 99(5), 1086-1105.
Lornage X, Schartner V, Balbueno I et al.Clinical, histological, and genetic characterization of PYROXD1-related myopathy. Acta neuropathologica communications 2019, 7(1),1-10.
Daimagüler HS, Akpulat, U, Özdemir Ö et al.Clinical and genetic characterization of PYROXD1‐related myopathy patients from Turkey. American Journal of Medical Genetics Part A 2021, 185(6), 1678-1690.
Tasca G, D'Amico A, Monforte M et al. Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1. Neuromuscular Disorders 2015, 25(11), 898-903.
Ullmann U, D'Argenzio L, Mathur S et al. ECEL1 gene related contractural syndrome: Long-term follow-up and update on clinical and pathological aspects. Neuromuscular Disorders 2018, 28(9), 741-749.
Yamaguchi T, Takano K, Inaba Y et al. PIEZO2 deficiency is a recognizable arthrogryposis syndrome: a new case and literature review. American Journal of Medical Genetics Part A 2019, 179(6), 948-957.
Harmelink M. Differentiating Congenital Myopathy from Congenital Muscular Dystrophy. Clinics in perinatology, 2019, 47.1: 197-209.
Manganelli F and Lucia Ruggiero. "Clinical features of Pompe disease." Acta Myologica 32.2 (2013): 82
Filli L,Winklhofer S,Andreisek G, Del Grande F. Imaging of myopathies. Radiologic Clinics 2017, 55(5),1055-1070.
Jungbluth H, Ochala J, Treves S, Gautel M. Current and future therapeutic approaches to the congenital myopathies. In Seminars in cell & developmental biology 2017;64,191-200.
Bellinger AM, Reiken S, Dura M et al. Remodeling of ryanodine receptor complex causes “leaky” channels: a molecular mechanism for decreased exercise capacity. Proceedings of the National Academy of Sciences 2008, 105(6), 2198-2202.
Lanner JT, Georgiou DK, Dagnino-Acosta A et al., AICAR prevents heat-induced sudden death in RyR1 mutant mice independent of AMPK activation. Nature medicine 2012,18(2), 244-251.
Todd JJ., Lawal TA, Witherspoon JW et al. Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies. Neurology 2020, 94(13), e1434-e1444.
Natera-de Benito D, Nascimento A, Abicht A et al. KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors, J. Neurol. 263 (3) (2016) 517–523.
Maani N, Karolczak S,Dowling JJ. James J. Genetic therapy for congenital myopathies. Curr Opin Neurol 2021,33:000-000.
Winter L,Staszewska I, Mihailovska E et al. Chemical chaperone ameliorates pathological protein aggregation in plectin-deficient muscle, J. Clin. Invest. 124 (3) (2014) 1144–1157.
Childers K, Joubert R, Poulard K et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy, Sci. Transl. Med. 6 (220) (2014), 220ra10.
Shieh PB, Kuntz N, Smith B et al. ASPIRO gene therapy trial In X-linked myotubular myopathy (XLMTM): update on preliminary safety and efficacy findings up to 72 weeks post-treatment 2020(1053).
